The retrospective analysis encouraged the European scientists, including Barker and Björklund, to launch a new trial, which is funded by the European Union, involving fetal dopaminergic-neuron transplants. Known as TRANSEURO, it will monitor disease progression in 150 patients in the United Kingdom, Sweden, France and Germany. The first patient is due for transplantation next month at Addenbrooke’s Hospital in Cambridge. In line with the retro*spective findings, the average age of trial participants at recruitment was 55, and their average disease duration just 4 years.

http://www.nature.com/news/fetal-cel...nson-s-1.15387